|
1
|
Johnston DL, Keene D, Strother D, Taneva
M, Lafay-Cousin L, Fryer C, Scheinemann K, Carret AS, Fleming A,
Afzal S, et al: Survival following tumor recurrence in children
with medulloblastoma. J Pediatr Hematol Oncol. 40:e159–e163. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Board PDQPTE, . Childhood medulloblastoma
and other central nervous system embryonal tumors treatment
(PDQ®). PDQ Cancer Information Summaries. National
Cancer Institute; Bethesda, MD: 2008
|
|
3
|
Khattab A and Monga DK: Turcot syndrome.
StatPearls. StatPearls Publishing; Treasure Island, FL: 2022
|
|
4
|
Onodera S, Nakamura Y and Azuma T: Gorlin
syndrome: Recent advances in genetic testing and molecular and
cellular biological research. Int J Mol Sci. 21:75592020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ostrom QT, Gittleman H, Truitt G, Boscia
A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report:
Primary brain and other central nervous system tumors diagnosed in
the United States in 2011–2015. Neuro Oncol. 20 (Suppl 4):iv1–iv86.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zapletalová D, André N, Deak L, Kyr M,
Bajciova V, Mudry P, Dubska L, Demlova R, Pavelka Z, Zitterbart K,
et al: Metronomic chemotherapy with the COMBAT regimen in advanced
pediatric malignancies: A multicenter experience. Oncology.
82:249–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Panigrahy D, Kaipainen A, Butterfield CE,
Chaponis DM, Laforme AM, Folkman J and Kieran MW: Inhibition of
tumor angiogenesis by oral etoposide. Exp Ther Med. 1:739–746.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pasquier E, Kavallaris M and André N:
Metronomic chemotherapy: New rationale for new directions. Nat Rev
Clin Oncol. 7:455–465. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eckerdt F, Clymer J, Bell JB, Beauchamp
EM, Blyth GT, Goldman S and Platanias LC: Pharmacological mTOR
targeting enhances the antineoplastic effects of selective PI3Kα
inhibition in medulloblastoma. Sci Rep. 9:128222019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chaturvedi NK, Kling MJ, Coulter DW,
McGuire TR, Ray S, Kesherwani V, Joshi SS and Sharp JG: Improved
therapy for medulloblastoma: Targeting hedgehog and PI3K-mTOR
signaling pathways in combination with chemotherapy. Oncotarget.
9:16619–16633. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Borders EB, Binova C and Medina PJ:
Mammalian target of rapamycin: Biological function and target for
novel anticancer agents. Am J Health Syst Pharm. 67:2095–2106.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brown RE, Tan D, Taylor JS, Miller M,
Prichard JW and Kott MM: Morphoproteomic confirmation of
constitutively activated mTOR, ERK, and NF-kappaB pathways in high
risk neuro-blastoma, with cell cycle and protein analyte
correlates. Ann Clin Lab Sci. 37:141–147. 2007.PubMed/NCBI
|
|
13
|
Zenali MJ, Zhang PL, Bendel AE and Brown
RE: Morphoproteomic confirmation of constitutively activated mTOR,
ERK, and NF-kappaB pathways in Ewing family of tumors. Ann Clin Lab
Sci. 39:160–166. 2009.PubMed/NCBI
|
|
14
|
Mateo-Lozano S, Gokhale PC, Soldatenkov
VA, Dritschilo A, Tirado OM and Notario V: Combined transcriptional
and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin
Cancer Res. 12:6781–6790. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Houghton PJ, Morton CL, Kolb EA, Gorlick
R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA and
Smith MA: Initial testing (stage 1) of the mTOR inhibitor rapamycin
by the pediatric preclinical testing program. Pediatr Blood Cancer.
50:799–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Johnsen JI, Segerström L, Orrego A, Elfman
L, Henriksson M, Kågedal B, Eksborg S, Sveinbjörnsson B and Kogner
P: Inhibitors of mammalian target of rapamycin downregulate MYCN
protein expression and inhibit neuroblastoma growth in vitro and in
vivo. Oncogene. 27:2910–2922. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vo KT, Karski EE, Nasholm NM, Allen S,
Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK
and DuBois SG: Phase 1 study of sirolimus in combination with oral
cyclophosphamide and topotecan in children and young adults with
relapsed and refractory solid tumors. Oncotarget. 8:23851–23861.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Houghton PJ, Morton CL, Gorlick R, Lock
RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, et
al: Stage 2 combination testing of rapamycin with cytotoxic agents
by the pediatric preclinical testing program. Mol Cancer Ther.
9:101–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Semela D, Piguet AC, Kolev M, Schmitter K,
Hlushchuk R, Djonov V, Stoupis C and Dufour JF: Vascular remodeling
and antitumoral effects of mTOR inhibition in a rat model of
hepatocellular carcinoma. J Hepatol. 46:840–848. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guba M, von Breitenbuch P, Steinbauer M,
Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S,
Anthuber M, et al: Rapamycin inhibits primary and metastatic tumor
growth by antiangiogenesis: Involvement of vascular endothelial
growth factor. Nat Med. 8:128–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qayed M, Cash T, Tighiouart M, MacDonald
T, Goldsmith KC, KeanPatty Church LS and Katzenstein HM: A phase I
study of sirolimus in combination with metronomic therapy in
children with recurrent and refractory solid/CNS tumors. J Clin
Oncol. May 20–2015.(Epub ahead of print). View Article : Google Scholar
|
|
22
|
Morgenstern DA, Marzouki M, Bartels U,
Irwin MS, Sholler GL, Gammon J, Yankanah R, Wu B, Samson Y and
Baruchel S: Phase I study of vinblastine and sirolimus in pediatric
patients with recurrent or refractory solid tumors. Pediatr Blood
Cancer. 61:128–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cash T: Sirolimus in combination with
metronomic chemotherapy in children with recurrent and/or
refractory solid and CNS tumors (AflacST1502). ClinicalTrials.govIdentifier: NCT02574728. 2022.
|
|
24
|
Putnam AR and Wallentine JC: Diagnostic
Pathology: Pediatric Neoplasms. Salt Lake City, UT: pp.
pp9842012
|
|
25
|
Ole Juhnke B, Mynarek M, von Hoff K,
Klagges S, Kortmann RD and Rutkowski S: HIT-MED guidance for
patients with newly diagnosed medulloblastoma ependymoma CNS
embryonal tumour and pineoblastoma. Version 4.0-02. 2017.
|
|
26
|
Alammar H, Nassani R, Alshehri MM,
Aljohani AA and Alrfaei BM: Deficiency in the treatment description
of mTOR inhibitor resistance in medulloblastoma, a systematic
review. Int J Mol Sci. 23:4642021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wen J and Hadden MK: Medulloblastoma drugs
in development: Current leads, trials and drawbacks. Eur J Med
Chem. 215:1132682021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kumar V, Kumar V, McGuire T, Coulter DW,
Sharp JG and Mahato RI: Challenges and recent advances in
medulloblastoma therapy. Trends Pharmacol Sci. 38:1061–1084. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
von Bueren AO, von Hoff K, Pietsch T,
Gerber NU, Warmuth-Metz M, Deinlein F, Zwiener I, Faldum A,
Fleischhack G, Benesch M, et al: Treatment of young children with
localized medulloblastoma by chemotherapy alone: Results of the
prospective, multicenter trial HIT 2000 confirming the prognostic
impact of histology. Neuro Oncol. 13:669–679. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bahl A and Bakhshi S: Metronomic
chemotherapy in progressive pediatric malignancies: Old drugs in
new package. Indian J Pediatr. 79:1617–1622. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bowers DC, Aquino VM, Leavey PJ, Bash RO,
Journeycake JM, Tomlinson G, Mulne AF, Haynes HJ and Winick NJ:
Phase I study of oral cyclophosphamide and oral topotecan for
children with recurrent or refractory solid tumors. Pediatr Blood
Cancer. 42:93–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sterba J, Pavelka Z, Andre N, Ventruba J,
Skotakova J, Bajciova V, Bronisova D, Dubska L and Valik D: Second
complete remission of relapsed medulloblastoma induced by
metronomic chemotherapy. Pediatr Blood Cancer. 54:616–617. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peyrl A, Chocholous M, Kieran MW, Azizi
AA, Prucker C, Czech T, Dieckmann K, Schmook MT, Haberler C, Leiss
U and Slavc I: Antiangiogenic metronomic therapy for children with
recurrent embryonal brain tumors. Pediatr Blood Cancer. 59:511–517.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoshida S, Amano H, Hayashi I, Kitasato H,
Kamata M, Inukai M, Yoshimura H and Majima M: COX-2/VEGF-dependent
facilitation of tumor-associated angiogenesis and tumor growth in
vivo. Lab Invest. 83:1385–1394. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
D'Amato RJ, Loughnan MS, Flynn E and
Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl
Acad Sci USA. 91:4082–4085. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carcamo B and Francia G: Cyclic metronomic
chemotherapy for pediatric tumors: Six case reports and a review of
the literature. J Clin Med. 11:28492022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Slavc I, Peyrl A, Gojo J, Holm S, Blomgren
K, Sehested AM, Leblond P and Czech T: MBCL-43. Reccurent
medulloblastoma-long-term survival with a ‘MEMMAT’ based
antiangiogenic approach. Neuro Oncol. 22 (Suppl 3):iii3972020.
View Article : Google Scholar
|
|
39
|
Simsek C, Esin E and Yalcin S: Metronomic
chemotherapy: A systematic review of the literature and clinical
experience. J Oncol. 2019:54837912019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Stempak D, Gammon J, Halton J, Moghrabi A,
Koren G and Baruchel S: A pilot pharmacokinetic and antiangiogenic
biomarker study of celecoxib and low-dose metronomic vinblastine or
cyclophosphamide in pediatric recurrent solid tumors. J Pediatr
Hematol Oncol. 28:720–728. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sterba J, Valik D, Mudry P, Kepak T,
Pavelka Z, Bajciova V, Zitterbart K, Kadlecova V and Mazanek P:
Combined biodifferentiating and antiangiogenic oral metronomic
therapy is feasible and effective in relapsed solid tumors in
children: Single-center pilot study. Onkologie. 29:308–313.
2006.PubMed/NCBI
|
|
42
|
Allen CE, Laetsch TW, Mody R, Irwin MS,
Lim MS, Adamson PC, Seibel NL, Parsons DW, Cho YJ and Janeway K;
Pediatric MATCH Target and Agent Prioritization Committee, . Target
and agent prioritization for the children's oncology group-national
cancer institute pediatric MATCH trial. J Natl Cancer Inst.
109:djw2742017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
De Vita S, De Matteis S, Laurenti L,
Chiusolo P, Reddiconto G, Fiorini A, Leone G and Sica S: Secondary
Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol.
84:760–762. 2005. View Article : Google Scholar : PubMed/NCBI
|
